Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects
A Randomized, Open-label, Three-period, Multiple Dosing Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacodynamics of Clopidogrel in Healthy Subjects
Sponsor: HK inno.N Corporation
Listed as NCT06164834, this PHASE1 trial focuses on Healthy and remains ongoing. Sponsored by HK inno.N Corporation, it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE1
Status: Not Yet Recruiting → Unknown
-
Sep 2025 — Feb 2026 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Dec 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- HK inno.N Corporation
For direct contact, visit the study record on ClinicalTrials.gov .